UCB, Inc. drugs
9 results
Bimzelx (bimekizumab)
(bimekizumab)UCB, Inc.
Usage: BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who are candidates for systemic therapy or phototherapy.
Briviact (brivaracetam)
(brivaracetam)UCB, Inc.
Usage: BRIVIACT is indicated for the treatment of partial-onset seizures in patients aged 1 month and older.
Cimzia (certolizumab pegol)
(certolizumab pegol)UCB, Inc.
Usage: CIMZIA is indicated for treating adults and certain pediatric patients with moderately to severely active Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and moderate-to-severe plaque psoriasis. It is also used for polyarticular juvenile idiopathic arthritis and non-radiographic axial spondyloarthritis with objective signs of inflammation.
Fintepla (fenfluramine)
(fenfluramine)UCB, Inc.
Usage: FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.
Nayzilam (midazolam)
(midazolam)UCB, Inc.
Usage: NAYZILAM is indicated for the acute treatment of seizure clusters or repetitive seizures that differ from a patient's typical seizure pattern in individuals with epilepsy aged 12 and older.
Neupro (rotigotine)
(rotigotine)UCB, Inc.
Usage: NEUPRO is indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).
Rystiggo (rozanolixizumab)
(ROZANOLIXIZUMAB)UCB, Inc.
Usage: RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
Univasc (moexipril hydrochloride)
(moexipril hydrochloride)UCB, Inc.
Usage: Univasc® is indicated for treating hypertension, either alone or with thiazide diuretics. Caution is advised due to potential risks of agranulocytosis and variations in efficacy and angioedema rates between black and non-black patients.
Vimpat (lacosamide)
(lacosamide)UCB, Inc.
Usage: VIMPAT is indicated for treating partial-onset seizures in patients aged 1 month and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.